Physician profile
Amanda Morris
NPI 1316969579
$1,028.79
in general payments reported to CMS, 2019-2025
21 companies · $329 in 2025
The $329 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.76 · 2020: $13.60 · 2021: $47.30 · 2022: $102 · 2023: $243 · 2024: $261 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $191.88 | 2021-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $176.76 | 2019-2025 | Ozempic, Rybelsus |
| Medtronic, INC. | $119.45 | 2023-2024 | Signia, Intellis Adaptivestim |
| Exact Sciences Corporation | $92.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Tandem Diabetes Care, INC. | $81.61 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Pfizer INC. | $53.62 | 2021-2024 | |
| Boston Scientific Corporation | $47.30 | 2025 | Watchman Flx, Wavewriter Alpha Prime 16 |
| Terumo Medical Corporation | $30.39 | 2024 | Azur Cx Detachable |
| Abbvie INC. | $28.53 | 2025 | |
| Cleerly, INC. | $24.68 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Alexion Pharmaceuticals, INC. | $23.72 | 2025 | Strensiq |
| Teleflex LLC | $20.60 | 2025 | Deflux Metal Needle |
| Dexcom, INC. | $20.42 | 2025 | Dexcom G6 Transmitter |
| Neurocrine Biosciences, INC. | $20.01 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $19.89 | 2025 | Breztri |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $19.16 | 2025 | |
| Astellas Pharma US INC | $14.20 | 2024 | Veozah |
| Janssen Pharmaceuticals, INC | $13.60 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.55 | 2019 | |
| Abbott Laboratories | $11.20 | 2021 | |
| Phathom Pharmaceuticals, INC. | $7.15 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.